Kay Olmstead

Kay Olmstead is a co-founder and CEO of Nano PharmaSolutions. Dr. Olmstead has over 31 years of experience in pharmaceutical industry in both API (drug substance) and finished dosage form development.

Prior to founding Nano PharmaSolutions, Dr. Olmstead served numerous small to medium pharmaceutical companies in worldwide as a CMC subject matter expert, especially in poorly soluble drug development. During past 20 years, Dr. Olmstead played a lead role in the development and the FDA approval of five commercial drugs for San Diego based companies, including Santarus, Inc. (NASDAQ: SNTR | acquired by Salix in 2013 for $2.6 billion) and Intercept Pharmaceutical (NASDAQ: ICPT).

Dr. Olmstead has published more than 12 manuscripts and has 11 issued patents and 3 pending patent applications. Dr.Olmstead received Ph.D. degree in Organic Chemistry at Johns Hopkins University followed by a NIH post-doctoral fellowship at Stanford University. She currently serves on as the Global Pharma Key Opinion Leader for Korean Health Industry Development Institute (KHIDI).